BIO-TECHNE's Net Income Rises Despite Sales Dip

TL;DR

**TECH's net income is up, but watch that cash flow – it's a red flag for liquidity despite cost controls.**

AI Summary

BIO-TECHNE Corp reported a mixed financial performance for the quarter ended September 30, 2025. Net sales decreased slightly to $286.555 million from $289.458 million in the prior year, a 1.0% decline. Despite this, net earnings increased by 13.6% to $38.185 million, up from $33.600 million in the same period last year. This improvement was driven by a higher gross margin of $188.112 million (up from $183.017 million) and reduced operating expenses, which fell to $140.454 million from $143.030 million. Diluted earnings per share rose to $0.24 from $0.21. The company saw a significant decrease in net cash provided by operating activities, dropping to $27.585 million from $63.889 million, primarily due to changes in working capital, including a $27.403 million decrease in income taxes payable. Strategic investments include a $15 million investment in Spear Bio in July 2024 and the ongoing forward contract to acquire Wilson Wolf Corporation, with the second milestone potentially triggering a $1 billion acquisition. Foreign currency translation resulted in a loss of $2.850 million, contrasting with a gain of $21.256 million in the prior year.

Why It Matters

For investors, the increase in net earnings and diluted EPS despite a slight revenue decline suggests effective cost management and improved operational efficiency, which could signal a healthier bottom line. However, the significant drop in operating cash flow, largely due to working capital changes, warrants closer scrutiny as it impacts liquidity and future investment capacity. The ongoing strategic acquisition of Wilson Wolf, potentially valued at over $1 billion, positions BIO-TECHNE for future growth in cell culture devices, but also introduces substantial financial commitment and integration risk. Competitively, this move could strengthen its market position against rivals in the life sciences tools sector, while the investment in Spear Bio indicates a focus on emerging technologies.

Risk Assessment

Risk Level: medium — The risk level is medium due to the significant decrease in net cash provided by operating activities, which fell from $63.889 million in Q3 2024 to $27.585 million in Q3 2025, a 56.9% reduction. This is largely attributed to a $27.403 million decrease in income taxes payable and a $22.101 million decrease in salaries, wages, and related accruals. Additionally, the company faces substantial future financial commitments, including a potential $1 billion acquisition of Wilson Wolf Corporation, which could strain financial resources if not managed effectively.

Analyst Insight

Investors should monitor BIO-TECHNE's cash flow statements closely in upcoming quarters to ensure the operating cash flow decline is a temporary working capital fluctuation rather than a systemic issue. While the improved net earnings are positive, the significant future acquisition commitment for Wilson Wolf warrants a careful assessment of the company's debt levels and integration strategy before making further investment decisions.

Financial Highlights

debt To Equity

0.29

revenue

$286.555M

operating Margin

16.6%

total Assets

$2,526.148M

total Debt

$300.000M

net Income

$38.185M

eps

$0.24

gross Margin

65.6%

cash Position

$144.962M

revenue Growth

-1.0%

Revenue Breakdown

Key Numbers

• $286.555M — Net Sales (Decreased 1.0% from $289.458M in Q3 2024)
• $38.185M — Net Earnings (Increased 13.6% from $33.600M in Q3 2024)
• $0.24 — Diluted EPS (Increased from $0.21 in Q3 2024)
• $27.585M — Net Cash from Operating Activities (Decreased 56.9% from $63.889M in Q3 2024)
• $140.454M — Total Operating Expenses (Decreased from $143.030M in Q3 2024)
• $188.112M — Gross Margin (Increased from $183.017M in Q3 2024)
• $1 billion — Potential Wilson Wolf Acquisition (Future financial commitment based on revenue milestone)
• $15 million — Spear Bio Investment (Cost-method investment made in July 2024)
• ($2.850M) — Foreign Currency Translation (Loss in Q3 2025 compared to $21.256M gain in Q3 2024)
• $46.000M — Long-term Debt Repayments (Repaid in Q3 2025, up from $19.000M in Q3 2024)

Key Players & Entities

• BIO-TECHNE Corp (company) — registrant
• Wilson Wolf Corporation (company) — acquisition target
• Spear Bio (company) — investment
• MDxHealth SA (company) — divestiture recipient
• SEC (regulator) — filing oversight
• NASDAQ Stock Market LLC (regulator) — stock exchange
• $286.555 million (dollar_amount) — net sales for Q3 2025
• $38.185 million (dollar_amount) — net earnings for Q3 2025
• $1 billion (dollar_amount) — potential acquisition cost for Wilson Wolf
• $15 million (dollar_amount) — investment in Spear Bio

FAQ

Risk Factors

• Working Capital Fluctuations [medium — financial]: A significant decrease in net cash provided by operating activities to $27.585M from $63.889M was primarily due to changes in working capital. A $27.403M decrease in income taxes payable was a notable factor, indicating potential shifts in tax payment timing or liabilities.
• Foreign Currency Translation Losses [medium — financial]: The company experienced a foreign currency translation loss of $2.850M in the current quarter, a stark contrast to a gain of $21.256M in the prior year. This volatility can impact reported earnings and cash flows.
• Strategic Acquisition Integration [high — operational]: The ongoing forward contract to acquire Wilson Wolf Corporation, with a potential $1 billion acquisition triggered by a revenue milestone, presents a significant future financial commitment and integration risk. The $15 million investment in Spear Bio also adds to strategic investment considerations.
• Competitive Landscape [medium — market]: The biotechnology sector is highly competitive, with constant innovation and pricing pressures. Maintaining market share and profitability requires continuous investment in R&D and effective sales strategies.
• Regulatory Compliance [high — regulatory]: As a life sciences company, BIO-TECHNE is subject to stringent regulatory requirements from bodies like the FDA. Non-compliance can lead to product recalls, fines, and reputational damage.

Industry Context

The life sciences and diagnostics industry is characterized by rapid technological advancements, significant R&D investment, and a complex regulatory environment. Companies like BIO-TECHNE operate in a competitive landscape, facing pressure from both large established players and agile startups. Trends include increasing demand for personalized medicine, advanced diagnostics, and automation in research.

Regulatory Implications

BIO-TECHNE operates under strict regulatory oversight, particularly concerning product quality and manufacturing processes. Compliance with FDA and other global health authority regulations is paramount. Any deviations can lead to significant financial penalties, product recalls, and damage to the company's reputation, impacting future sales and market access.

What Investors Should Do

1. Monitor working capital trends
2. Evaluate the impact of foreign currency fluctuations
3. Assess progress on strategic acquisitions
4. Analyze gross and operating margin trends

Key Dates

• 2025-09-30: Quarter ended September 30, 2025 — Reporting period for the financial results discussed in the 10-Q.
• 2024-07-01: Spear Bio Investment — A strategic investment of $15 million was made, indicating expansion into new technologies or markets.
• 2024-09-30: Prior Year Quarter — Provides a crucial benchmark for year-over-year performance comparison.

Glossary

Gross Margin

The difference between revenue and the cost of goods sold, representing profitability before operating expenses. (Increased to $188.112M from $183.017M, indicating improved efficiency in production or pricing power.)

Operating Expenses

Costs incurred in the normal course of business, excluding cost of goods sold, such as selling, general, and administrative expenses, and research and development. (Decreased to $140.454M from $143.030M, contributing to higher operating income.)

Net Cash Provided by Operating Activities

The cash generated from a company's normal business operations. (Significantly decreased to $27.585M from $63.889M, primarily due to working capital changes, raising concerns about short-term cash generation.)

Foreign Currency Translation

The process of converting financial statement balances denominated in a foreign currency into the reporting currency. (Resulted in a loss of $2.850M, a negative swing from a significant gain in the prior year, impacting comprehensive income.)

Contract Liabilities

Obligations to transfer goods or services to a customer for which the company has received consideration from the customer. (Stood at $30.445M, a slight decrease from $32.571M, reflecting revenue recognition patterns.)

Goodwill

An intangible asset that arises when one company acquires another for a price that is higher than the fair market value of its net assets. (Remained substantial at $978.912M, indicating past acquisitions and potential impairment risk if acquired businesses underperform.)

Year-Over-Year Comparison

Compared to the prior year's quarter, BIO-TECHNE Corp saw a slight 1.0% decrease in net sales to $286.555 million. However, net earnings showed a robust 13.6% increase to $38.185 million, driven by an improved gross margin ($188.112M vs $183.017M) and reduced operating expenses ($140.454M vs $143.030M). A key concern is the substantial 56.9% decline in net cash from operating activities, largely attributed to working capital shifts, and a negative swing in foreign currency translation from a $21.256M gain to a $2.850M loss.

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value TECH The NASDAQ Stock Mar

Filing Documents

• tech-20250930x10q.htm (10-Q) — 1807KB
• tech-20250930xex31d1.htm (EX-31.1) — 9KB
• tech-20250930xex31d2.htm (EX-31.2) — 9KB
• tech-20250930xex32d1.htm (EX-32.1) — 5KB
• tech-20250930xex32d2.htm (EX-32.2) — 5KB
• 0001104659-25-107053.txt ( ) — 9284KB
• tech-20250930.xsd (EX-101.SCH) — 49KB
• tech-20250930_cal.xml (EX-101.CAL) — 73KB
• tech-20250930_def.xml (EX-101.DEF) — 195KB
• tech-20250930_lab.xml (EX-101.LAB) — 469KB
• tech-20250930_pre.xml (EX-101.PRE) — 365KB
• tech-20250930x10q_htm.xml (XML) — 2107KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements (Unaudited) 1 Condensed Consolidated Statements of Earnings and Comprehensive Income 1 Condensed Consolidated Balance Sheets 2 Condensed Consolidated Statements of Cash Flows 3 Condensed Consolidated Statements of Stockholders' Equity 4 Notes to Condensed Consolidated Financial Statements 5 Note 1. Basis of Presentation and Summary of Significant Accounting Policies 5 Note 2. Revenue Recognition 6 Note 3. Selected Balance Sheet Information 8 Note 4. Fair Value Measurements 10 Note 5. Debt and Other Financing Arrangements 12 Note 6. Leases 12 Note 7. Supplemental Equity and Accumulated Other Comprehensive Income (Loss) 14 Note 8. Earnings Per Share 15 Note 9. Share-based Compensation and Other Benefit Plans 15 Note 10. Other Income/(Expense) 16 Note 11. Income Taxes 16 Note 12. Segment Information 16 Note 13. Restructuring 18 Note 14. Subsequent Events 20 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 28 Item 4.

Controls and Procedures

Controls and Procedures 28

: OTHER INFORMATION

PART II: OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 28 Item 1A.

Risk Factors

Risk Factors 28 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 28 Item 3. Defaults Upon Senior Securities 29 Item 4. Mine Safety Disclosures 29 Item 5. Other Information 29 Item 6. Exhibits 30

SIGNATURES

SIGNATURES 31 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME Bio-Techne Corporation and Subsidiaries (in thousands, except per share data) (unaudited) Quarter Ended September 30, 2025 2024 Net sales $ 286,555 $ 289,458 Cost of sales 98,443 106,441 Gross margin 188,112 183,017 Operating expenses: Selling, general and administrative 116,213 119,161 Research and development 24,241 23,869 Total operating expenses 140,454 143,030 Operating income 47,658 39,987 Other income (expense) 333 184 Earnings before income taxes 47,991 40,171 Income taxes 9,806 6,571 Net earnings $ 38,185 $ 33,600 Other comprehensive income (loss): Foreign currency translation income (loss) ( 2,850 ) 21,256 Unrealized gains (losses) on derivative instruments ( 1,665 ) ( 3,027 ) Other comprehensive income (loss) ( 4,515 ) 18,229 Comprehensive income $ 33,670 $ 51,829 Earnings per share: Basic $ 0.25 $ 0.21 Diluted $ 0.24 $ 0.21 Weighted average common shares outstanding: Basic 155,464 158,531 Diluted 156,362 161,115 See Notes to Condensed Consolidated Financial Statements. 1 Table of Contents CONDENSED CONSOLIDATED BALANCE SHEETS Bio-Techne Corporation and Subsidiaries (in thousands, except share and per share data) September 30, 2025 June 30, (unaudited) 2025 ASSETS Current assets: Cash and cash equivalents $ 144,962 $ 162,186 Accounts receivable, less allowances of $ 4,375 and $ 4,215 , respectively 183,897 206,876 Inventories 203,188 189,446 Current assets held-for-sale — 12,332 Other current assets 77,460 37,460 Total current assets 609,507 608,300 Property and equipment, net 240,334 245,719 Right-of-use assets 70,725 73,399 Goodwill 978,912 980,935 Intangible assets, net 350,107 365,599 Other assets 276,563 283,916 Total assets $ 2

View Full Filing

View this 10-Q filing on SEC EDGAR